Individual Predispositions in Healthy Vasospastic Individuals: Patient Profiling for Targeted Prevention of "Down-Stream" Pathologies as Cost-Effective Personalised Medicine

Advances in Predictive, Preventive and Personalised Medicine

Volumn 3, Issue , 2013, Pages 13-29

  Yeghiazaryan, Kristina ^a   Flammer, Josef ^b   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Blood biomarkers; Glaucoma; Personalised medicine; Predictive diagnostics; Targeted prevention; Vascular deregulation

Indexed keywords

GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN P53; PURINERGIC P2Y2 RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DNA DAMAGE; EYE DISEASE; GENE EXPRESSION; GLAUCOMA; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; OCULAR ISCHAEMIA; OPTIC NERVE DISEASE; PERSONALIZED MEDICINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNINDEXED SEQUENCE; UPREGULATION; VASCULAR DEREGULATION; VASOSPASTIC SYNDROME;

EID: 84927704169     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: 10.1007/978-94-007-5866-7_2     Document Type: Article

References (43)

1. Flammer J, Pache M, Resink T (2001) Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 20: 319-349.
2. Mozaffarieh M, Fraenkl S, Konieczka K, Flammer J (2010) Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy. EPMA J 1: 229-236.
3. Beltrame JF, Sasayama S, Maseri A (1999) Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 33: 1442-1452.
4. Flammer J (2006) Glaucoma. A guide for patients. An introduction for care providers. A quick reference. 3rd revised edn. Hogrefe & Huber Publishers, Bern.
5. Teuchner B, Orgül S, Ulmer H, Haufschild T, Flammer J (2004) Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand 82: 738-740.
6. Wunderlich K, Zimmerman C, Gutmann H, Teuchner B, Flammer J, Drewe J (2003) Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol Vis 9: 756-761.
7. Flammer J (2001) Innovative glaucoma therapy. Ophthalmologe 98: 923-924.
8. Finsterer J (2004) Mitochondriopathies. Eur J Neurol 11: 163-186.
9. Flammer J, Guthauser U, Mahler F (1987) Do ocular vasospasms help cause low-tension glaucoma? Doc Ophthalmol Proc Ser 49: 397-399.
10. Guthauser U, Flammer J, Mahler F (1988) The relationship between digital and ocular vasospasm. Graefes Arch Clin Exp Ophthalmol 226: 224-226.
11. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefánsson E (2002) The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 21: 359-393.
12. Golubnitschaja O, Wunderlich K, Decker C, Mönkemann H, Schild HH, Flammer J (2002) Molecular imaging of perfusion disturbances in glaucoma. Amino Acids 23: 293-299.
13. Golubnitschaja O, Yeghiazaryan K, Liu R, Mönkemann H, Leppert D, Schild H, Haefliger IO, Flammer J (2004) Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma 13: 66-72.
14. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J (2000) Altered gene expression in lymphocytes of patients with normal-tension glaucoma. Curr Eye Res 21: 867-876.
15. Wunderlich K, Golubnitschaja O, Pache M, Eberle AN, Flammer J (2002) Increased plasma levels of 20S proteasome alpha-subunit in glaucoma patients: an observational pilot study. Mol Vis 8: 431-435.
16. Yeghiazaryan K, Flammer J, Orgül S, Wunderlich K, Golubnitschaja O (2009) Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis 15: 2339-2348.
17. Golubnitschaja O, Yeghiazaryan K, Flammer J (2010) Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J 1: 237-244.
18. Fraenkl SA, Mozaffarieh M, Flammer J (2010) Retinal vein occlusions: the potential impact of a dysregulation of the retinal veins. EPMA J 1: 253-261.
19. Golubnitschaja O, Flammer J (2007)What are the biomarkers for glaucoma? Surv Ophthalmol 52: S155-S161.
20. Golubnitschaja O, Yeghiazaryan K, Flammer J (2013) Glaucomatous optic neuropathy: risk assessment and potential targets for effective prevention and treatments tailored to the patient. In: Mandel S (ed) Neurodegenerative diseases: integrative PPPM approach as the medicine of the future. Book series: Advances in PPPM. Golubnitschaja O (ed). Springer, Dordrecht, pp. 187-201.
21. Golubnitschaja O, Yeghiazaryan K, Orgül S, Flammer J (2009) What are the biomarkers for glaucoma? In: Golubnitshaja O (ed) Predictive diagnostics and personalized treatment: dream or reality. Nova Science Publishers, New York.
22. Moenkemann H, Flammer J, Wunderlich K, Breipohl W, Schild HH, Golubnitschaja O (2005) Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals. Amino Acid 28: 199-205.
23. Golubnitschaja O, Moenkemann H, Kim K, Mozaffari MS (2003) DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem Pharmacol 66: 511-517.
24. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26: 587-595.
25. Golubnitschaja O, Yeghiazaryan K, Wunderlich K, Schild HH, Flammer J (2007) Disease proteomics reveals altered basic gene expression regulation in leukocytes of glaucoma patients. Proteomics Clin Appl 1: 1316-1323.
26. Kannan S (2002) Amplification of extracellular nucleotide-induced leukocyte(s) degranulation by contingent autocrine and paracrine mode of leukotriene-mediated chemokine receptor activation. Med Hypotheses 59: 261-265.
27. Di Gennaro A, Carnini C, Buccellati C, Ballerio R, Zarini S, Fumagalli F, Viappiani S, Librizzi L, Hernandez A, Murphy RC, Constantin G, De Curtis M, Folco G, Sala A (2004) Cysteinylleukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J 18: 842-844.
28. Rosnowska M, Cendrowski W, Sobczyk W(1997) Leukotrienes B4 and C4 in cerebrospinal of patients with multiple sclerosis. Pol Merkur Lekarski 2: 254-255.
29. Akbar GK, Dasari VR, Webb TE, Ayyanathan K, Pillarisetti K, Sandhu AK, Athwal RS, Daniel JL, Ashby B, Barnard EA, Kunapuli SP (1996) Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem 271: 18363-18367.
30. Dasari VR, Jin J, Kunapuli SP (2000) Distribution of leukotriene B4 receptors in human hematopoietic cells. Immunopharmacology 48: 157-163.
31. Tager AM, Luster AD (2003) BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandin Leukot Essent Fatty Acid 69: 123-134.
32. Pintor J, Peral A, Peláez T, Martín S, Hoyle CH (2003) Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure. J Pharmacol Exp Ther 304: 342-348.
33. Akopov SE, Sercombe R, Seylaz J (1995) Actions of platelet activating factor on isolated rabbit basilar artery: modulation by activated polymorphonuclear leukocytes. J Vasc Res 32: 49-57.
34. Akopov S, Sercombe R, Seylaz J (1996) Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev 8: 11-94.
35. Butcher EC (1991) Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67: 1033-1036.
36. Barone FC, Feuerstein GZ (1999) Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 19: 819-834.
37. Chen H, ChoppM, Zhang RL, Bodzin G, Chen Q, Rusche JR, Todd RF 3rd (1994) Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 35: 458-463.
38. Connolly ES Jr, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, Stern DM, Solomon RA, Gutierrez-Ramos JC, Pinsky DJ (1996) Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 97: 209-216.
39. Horiguchi M, Kimura M, Skurnick J, Aviv A (1998) Parameters of lymphocyte NaC-Ca2C regulation and blood pressure: the gender effect. Hypertension 32: 869-874.
40. Marrelli SP (2001) Mechanisms of endothelial P2Y(1)-and P2Y(2)-mediated vasodilatation involve differential [Ca2C]I responses. Am J Physiol Heart Circ Physiol 281: H1759-H1766.
41. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
42. Kunapuli SP, Daniel JL (1998) P2 receptor subtypes in the cardiovascular system. Biochem J 336: 513-523.
43. Yeghiazaryan K, Flammer J, Golubnitschaja O (2010) Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 1: 263-272.